grafa.com
Cure8 news brief
Why This Matters
New Phase 2a data suggest a combination therapy (ABBV-466) produced higher endoscopic remission at Week 24 than either component alone — a potential sign that multi-target approaches might improve Crohn's outcomes.
The results and safety signals will matter to people considering future treatment options and for clinicians watching emerging therapies.
Who Should Pay Attention
Adults with Crohn's disease, patients on or considering biologic therapy, gastroenterologists and IBD clinicians, and researchers studying combination immune-targeting strategies.
Study Snapshot
Story typeResearch news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
This is a press-style report about a company-run Phase 2a study of a combination treatment for Crohn's disease; it does not present a full peer-reviewed paper here. The remission numbers reported are endoscopic remission at Week 24 and the sample is described as roughly 300 patients in the TARGET-CD study.
The write-up mentions gene analyses suggesting intestinal tissue repair and lists SAE percentages for each arm, but does not provide detailed methods, randomization, statistical comparisons, or full safety breakdowns in the extracted text.
If you are following Crohn's treatment advances, this suggests combining therapies that target different inflammatory pathways is an active research approach and showed higher remission in this study set; however, the report is preliminary company-disclosed Phase 2a data pending scientific presentation and peer review.
Keep In Mind
This is a company report of Phase 2a trial results slated for presentation at a conference (UEG Week 2026). The article does not provide full trial methods, peer-reviewed publication, or detailed safety and statistical analyses. company press releases and media reports may precede formal peer-reviewed data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationgrafa.com
AuthorsIsaac Francis
Indexed viaGoogle News
Source typeWeb article
PublishedOct 19, 2026, 1:31 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie's Dual-Targeting Therapy Shows Higher Remission Rates In Mid-Stage Crohn's Disease Study
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
Therapies in development for Crohn’s disease target new pathways
These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...